{
  "id": 16732084,
  "title": "Valion Bio announces preferred stock and warrant sales totaling $4.77 million",
  "url": "https://urgent.news/2026/10/27/valion-bio-announces-preferred-stock-and-warrant-sales-totaling-4-77",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-27T10:12:51.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/sec-filings/valion-bio-announces-preferred-stock-and-warrant-sales-totaling-477-million-93CH-4974766"
  },
  "original_language": "en",
  "account": null,
  "summary": "Valion Bio, Inc. (VBIO) has announced the sale of $4.77 million worth of Series B and Series C Non-Voting Convertible Preferred Stock and related warrants. This capital raise comes as the company's stock trades at $0.84 per share, with a market capitalization of $750,000, down nearly 99% over the past year. Valion Bio is currently facing financial challenges, with a high debt-to-equity ratio of 4.1 and a significant burn rate. The company's shares are considered undervalued, according to InvestingPro Tips. The transactions were executed in private placements exempt from registration under the Securities Act of 1933 and/or Rule 506(b).",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}